Over the past decades, CD4 T cells have been considered as a supporting actor in the fields of cancer immunotherapy. Until recently, accumulating evidence has demonstrated the critical role of CD4 T cells during antitumor immunity. CD4 T cells can either suppress or promote the antitumor cytotoxic CD8 T cell responses, either in secondary lymphoid organs or in the tumor. In this review, we provide an overview of the multifaceted role of different CD4 T cell subsets in cancer immune response and their contribution during cancer therapies. Specifically, we focus on the latest progress regarding the impact of CD4 T cell modulation on immunotherapies and other cancer therapies and discuss the prospect for harnessing CD4 T cells to control tumor progression and prevent recurrence in patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750687 | PMC |
http://dx.doi.org/10.3390/cancers14010260 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!